Literature DB >> 28886949

Low antigen dose formulated in CAF09 adjuvant Favours a cytotoxic T-cell response following intraperitoneal immunization in Göttingen minipigs.

Nana H Overgaard1, Thomas M Frøsig1, Jeanne T Jakobsen1, Søren Buus2, Mads H Andersen3, Gregers Jungersen4.   

Abstract

The relationship between the antigen dose and the quality of an immune response generated upon immunization is poorly understood. However, findings show that the immune system is indeed influenced by the antigen dose; hence underlining the importance of correctly determining which dose to use in order to generate a certain type of immune response. To investigate this area further, we used Göttingen minipigs asan animal model especially due to the similar body size and high degree of immunome similarity between humans and pigs. In this study, we show that both a humoral and a cell-mediated immune (CMI) response can be generated following intraperitoneal immunization with tetanus toxoid (TT) formulated in the CAF09 liposomal adjuvant. Importantly, a low antigen dose induced more TT-specific polyfunctional T cells, whereas antigen-specific IgG production was observed upon high-dose immunization. Independent of antigen dose, intraperitoneal administration of antigen increased the amount of TT-specific cytotoxic CD8β+ T cells within the cytokine-producing T-cell pool when compared to the non-cytokine producing T-cell compartment. Taken together, these results demonstrate that a full protein formulated in the CAF09 adjuvant and administered to pigs via the intraperitoneal route effectively generates a cytotoxic T-cell response. Moreover, we confirm the inverse relationship between the antigen dose and the induction of polyfunctional T cells in a large animal model. These finding can have implications for the design of upcoming vaccine trials aiming at establishing a cytotoxic T-cell response.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Administration route; Antibody responses; Antigen dose; Cytokine production; Cytotoxic T cells; Immunization

Mesh:

Substances:

Year:  2017        PMID: 28886949     DOI: 10.1016/j.vaccine.2017.08.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.

Authors:  Yoshita Bhide; Wei Dong; Inta Gribonika; Daniëlle Voshart; Tjarko Meijerhof; Jacqueline de Vries-Idema; Stephen Norley; Kate Guilfoyle; Sarah Skeldon; Othmar G Engelhardt; Louis Boon; Dennis Christensen; Nils Lycke; Anke Huckriede
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

2.  Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults.

Authors:  Stéphane Pillet; Julie Couillard; Sonia Trépanier; Jean-François Poulin; Bader Yassine-Diab; Bruno Guy; Brian J Ward; Nathalie Landry
Journal:  PLoS One       Date:  2019-06-05       Impact factor: 3.240

3.  Göttingen Minipigs as a Model to Evaluate Longevity, Functionality, and Memory of Immune Response Induced by Pertussis Vaccines.

Authors:  Céline Vaure; Véronique Grégoire-Barou; Virginie Courtois; Emilie Chautard; Cyril Dégletagne; Yuanqing Liu
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 7.561

4.  Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.

Authors:  Sofie Kirial Mørk; Mohammad Kadivar; Kalijn Fredrike Bol; Arianna Draghi; Marie Christine Wulff Westergaard; Signe Koggersbøl Skadborg; Nana Overgaard; Anders Bundgård Sørensen; Ida Svahn Rasmussen; Lars Vibe Andreasen; Christina Westmose Yde; Thomas Trolle; Christian Garde; Jens Friis-Nielsen; Nis Nørgaard; Dennis Christensen; Jens Vindahl Kringelum; Marco Donia; Sine Reker Hadrup; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2022-01-10       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.